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The neurotransmitter serotonin (5-HT) has a multifaceted function in the modulation of
information processing through the activation of multiple receptor families, including
G-protein-coupled receptor subtypes (5-HT1, 5-HT2, 5-HT4–7) and ligand-gated ion channels
(5-HT3). The largest population of serotonergic neurons is located in the midbrain,
specifically in the raphe nuclei. Although the medial and dorsal raphe nucleus (DRN)
share common projecting areas, in the basal ganglia (BG) nuclei serotonergic innervations
come mainly from the DRN. The BG are a highly organized network of subcortical nuclei
composed of the striatum (caudate and putamen), subthalamic nucleus (STN), internal
and external globus pallidus (or entopeduncular nucleus in rodents, GPi/EP and GPe)
and substantia nigra (pars compacta, SNc, and pars reticulata, SNr). The BG are part of
the cortico-BG-thalamic circuits, which play a role in many functions like motor control,
emotion, and cognition and are critically involved in diseases such as Parkinson’s disease
(PD). This review provides an overview of serotonergic modulation of the BG at the
functional level and a discussion of how this interaction may be relevant to treating PD
and the motor complications induced by chronic treatment with L-DOPA.
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Serotonergic innervation in the brain originates from the raphe
nuclei. Both, the medial and the dorsal raphe nucleus (DRN),
project to common areas implicated in motor control, such as the
thalamus. Nevertheless, the basal ganglia (BG) nuclei receive sero-
tonergic afferences coming prevalently from the DRN (reviewed
in Di Matteo et al., 2008). The BG contain serotonin (5-HT) and
its metabolite 5-hydroxy-indolacetic acid (5-HIAA) (Palkovits
et al., 1974; Saavedra, 1977; Lavoie and Parent, 1990), 5-HT
transporter (SERT) and serotonergic receptors (from 5-HT1 to 5-
HT7). These serotonergic receptors are unevenly expressed along
the BG, and their distribution also differs between species. Here,
we will review the evidences supporting the serotonergic sys-
tem as a modulator of the BG functionality. Both physiological
and pathological conditions will be analyzed from the basic and
clinical point of view.
PHYSIOLOGICAL SEROTONERGIC MODULATION OF THE
BASAL GANGLIA
In accordance with its neuroanatomical distribution (as sum-
marized in Table 1), 5-HT physiologically modulates BG nuclei
activity by acting on serotonergic receptors.
STRIATUM
The striatum is the main input nucleus of the BG and a key
neural substrate for motor function. Several studies have shown
that 5-HT affects striatal function. In fact, both DRN stimula-
tion and local administration of 5-HT into the striatum inhibit
the vast majority of the striatal cells (Olpe and Koella, 1977;
Davies and Tongroach, 1978; Yakel et al., 1988). However, by per-
forming intracellular recordings, some researchers have reported
striatal excitatory postsynaptic potentials after DRN stimulation,
as well as a 5-HT-induced increase in firing rate of medium spiny
neurons (MSN) (Vandermaelen et al., 1979; Park et al., 1982;
Stefani et al., 1990; Wilms et al., 2001). Stimulation of presynap-
tic 5-HT1A and 5-HT1B receptors inhibits striatal 5-HT release
(Gerber et al., 1988; Knobelman et al., 2000), and these recep-
tors also control the release of other neurotransmitters in the
striatum. Accordingly, 5-HT1A receptor activation decreases glu-
tamate release from corticostriatal projections (Antonelli et al.,
2005; Mignon and Wolf, 2005; Dupre et al., 2011, 2013). On the
other hand, activation of 5-HT1B receptors indirectly stimulates
the substantia nigra pars compacta (SNc) by decreasing GABA
release from the substantia nigra pars reticulata (SNr), what conse-
quently leads to increasing striatal dopamine levels (Gerber et al.,
1988).
The 5-HT2 receptor family produces an inhibitory action
on striatal neuron activity, mainly by modulating MSN (el
Mansari et al., 1994; el Mansari and Blier, 1997). Moreover,
Rueter et al. (2000) have shown that 5-HT2C receptors exert
tonic inhibitory control over MSN membrane excitability. Other
in vivo studies, however, have shown contradictory results sug-
gesting that the effect of serotonergic drugs depends on the area
of the striatum analyzed (Wilms et al., 2001). 5-HT2 recep-
tor activation indirectly reduces the activity of striatal MSN
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Table 1 | Localization and expression density of serotonergic receptors in the basal ganglia of healthy brains of rodents, monkeys and humans.
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+++, strong; ++, moderate; +, weak/r, rodent; m, monkey; h, human. EP, entopeduncular nucleus; GPe, external segment of the globus pallidus; GPi, internal
segment of the globus pallidus; STN, subthalamic nucleus; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata.
by enhancing the inhibitory tone of cholinergic interneurons
over these output neurons. The increased release of acetyl-
choline is due to activation of cholinergic interneurons mainly
through 5-HT2C receptors, although the involvement of 5-HT6
and 5-HT7 receptors has also been demonstrated (Bonsi et al.,
2007; Blomeley and Bracci, 2009). In addition, the activa-
tion of 5-HT2C receptors located on fast-spiking interneu-
rons increases their excitability, causing an enhancement of
GABAergic postsynaptic inhibition that also decreases the
activity of striatal projecting neurons (Blomeley and Bracci,
2009).
SUBTHALAMIC NUCLEUS
5-HT exerts a complex effect in the subthalamic nucleus (STN)
that is considered to be a powerful excitatory drive in the BG
motor circuit. Both pharmacological lesion of the DRN and 5-HT
depletion increase STN firing frequency and burst activity in vivo
(Liu et al., 2007; Aristieta et al., 2013). Decreased and increased
excitability have been reported with the activation of 5-HT1A and
5-HT2C, and 5-HT4 receptors, respectively (Flores et al., 1995;
Stanford et al., 2005; Xiang et al., 2005; Shen et al., 2007; Aristieta
et al., 2013). In addition, activation of 5-HT1B receptors inhibits
synaptic activity of STN neurons (Barwick et al., 2000; Shen and
Johnson, 2008).
GLOBUS PALLIDUS
The globus pallidus (GP) has two segments, the external GP
(GPe), which has a central position in the BG loop, and the
internal GP (GPi/EP), which, together with the SNr, form the out-
put structures of the BG. In the GPe, 5-HT depletion decreases
the firing frequency and increases the proportion of bursty and
irregular neurons (Delaville et al., 2012b). In contrast, local appli-
cation of 5-HT or selective serotonin reuptake inhibitor (SSRI)
administration excites most of GPe neurons (Querejeta et al.,
2005; Zhang et al., 2010; Wang et al., 2013). These findings
have been further confirmed by a patch-clamp recording study
in which 5-HT perfusion produced a reversible depolarization
of the GP neuron membrane potential, thereby increasing the
firing rate of these neurons (Chen et al., 2008). In vivo stud-
ies indicate that the stimulatory effect of 5-HT on GPe neurons
is mediated by the activation of 5-HT4 or 5-HT7 postsynap-
tic receptors, but not 5-HT2C and 5-HT3 receptors (Bengtson
et al., 2004; Kita et al., 2007; Chen et al., 2008; Hashimoto
and Kita, 2008). In contrast, 5-HT can decrease the presynaptic
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release of glutamate and GABA from the subthalamopallidal
and striatopallidal terminals, respectively, through 5-HT1B recep-
tors (Querejeta et al., 2005). In addition, 5-HT has been pro-
posed to modulate the inhibitory and excitatory responses in
GPe electrical stimulation of the motor cortex in awake mon-
keys (Kita et al., 2007). In fact, 5-HT suppresses GABAergic
inhibitory responses to cortical stimulation through presynaptic
5-HT1B receptors and glutamatergic excitatory responses involv-
ing presynaptic or postsynaptic 5-HT1A receptors (Kita et al.,
2007).
Few studies have been conducted to investigate the effects
of 5-HT on the GPi/EP nucleus. Recently, it has been
shown that intra-EP administration of a 5-HT2 receptor
agonist promotes oral movements and inhibits EP neu-
ronal activity in dopamine-depleted rats (Lagiere et al.,
2013).
SUBSTANTIA NIGRA
Together with the GPi, the SNr constitutes the principal out-
put nucleus of the BG and plays a relevant role in move-
ment initiation. In this nucleus, 5-HT induces mostly an
inhibitory effect in vivo (Dray et al., 1976; Collingridge and
Davies, 1981), while 5-HT depletion decreases firing rate and
increases burst activity of SNr neurons (Delaville et al., 2012a).
Electrophysiological studies carried out in brain slices indi-
cate that 5-HT not only excites SNr neurons acting directly
on 5-HT2C receptors (Rick et al., 1995; Stanford and Lacey,
1996; Stanford et al., 2005) but also disinhibits SNr neu-
rons by reducing GABA release from striatonigral terminals via
presynaptic 5-HT1B receptor stimulation (Stanford and Lacey,
1996). A recent electrophysiological study reveals that presynap-
tic 5-HT1B receptor activation gates STN excitatory inputs to
the SNr and reduces burst firing activity of the SNr, and there-
fore may be critically involved in movement control (Ding et al.,
2013).
The role of 5-HT transmission in modulating the activ-
ity of dopaminergic SNc neurons is still unclear. Although
the effect of 5-HT input seems to be inhibitory (Sinton and
Fallon, 1988; Arborelius et al., 1993), chemical lesion of the
DRN does not significantly alter SNc activity and DRN electrical
stimulation only inhibits spontaneous activity in a subset of
neurons (Kelland et al., 1990). Further, SSRI administration
does not modulate SNc activity (Prisco and Esposito, 1995),
and 5-HT depletion has been shown to either decrease or
have no significant effect on SNc neuron excitability (Kelland
et al., 1990; Minabe et al., 1996). Non-selective 5-HT2 recep-
tor antagonists stimulate SNc neurons (Ugedo et al., 1989),
whereas 5-HT4 receptors selectively prevents the stimulatory
effect induced by haloperidol in this brain area (Lucas et al.,
2001).
IMPLICATION OF THE SEROTONERGIC SYSTEM IN
PARKINSON’S DISEASE
In the parkinsonian state and subsequent replacement ther-
apy with L-DOPA, the serotonergic system adapts to the
lack of dopamine by adopting anatomical and functional
transformations.
SEROTONERGIC SYSTEM IN PARKINSON’S DISEASE AND
PARKINSONIAN ANIMAL MODELS
Parkinson’s disease (PD) is a neurodegenerative disease typi-
fied by loss of dopaminergic neurons in the SNc and subse-
quent dopamine depletion in the striatum. In patients with
PD, it is generally supported that serotonergic neurotransmis-
sion decreases in advanced stages of the disease (Haapaniemi
et al., 2001; Kerenyi et al., 2003) since the DRN, in addition
to other nuclei, undergoes degeneration (Halliday et al., 1990;
Jellinger, 1990). Moreover, 5-HT and 5-HIAA concentrations,
as well as SERT expression, are reduced in several BG nuclei
(Scatton et al., 1983; Raisman et al., 1986; D’Amato et al., 1987;
Chinaglia et al., 1993; Kerenyi et al., 2003; Guttman et al.,
2007; Kish et al., 2008; Rylander et al., 2010). Regarding recep-
tor expression, 5-HT1A is decreased and 5-HT2C is increased in
some BG nuclei (Fox and Brotchie, 2000; Ballanger et al., 2012)
(Figure 1). Other serotonergic receptor (5-HT1B/D, 5-HT3, and
5-HT4) densities are however not modified by the dopaminer-
gic loss (Steward et al., 1993; Reynolds et al., 1995; Wong et al.,
1996; Castro et al., 1998). Overall, this dysfunctional serotonergic
neurotransmission can indeed be linked to the high prevalence of
depressive symptoms in parkinsonian patients (Reijnders et al.,
2008).
In animal models of parkinsonism, the changes occurring after
dopaminergic lesion have not been equally reproduced by dif-
ferent research groups. The discrepancies between these studies
may be due to different protocol paradigms used for inducing
the parkinsonian state, including the age of the animals, site
of injection, concentration of the toxin, and the time between
surgery and performing the studies. Several researchers have
reported hyperinnervation (Zhou et al., 1991; Rozas et al., 1998;
Balcioglu et al., 2003; Maeda et al., 2003), while others found
no sprouting (Prinz et al., 2013), or even a decrease in striatal
serotonergic fibers after dopaminergic damage (Takeuchi et al.,
1991; Rylander et al., 2010). Along the same lines, striatal 5-
HT levels have been found to be increased (Commins et al.,
1989; Zhou et al., 1991; Karstaedt et al., 1994; Balcioglu et al.,
2003), unchanged (Breese et al., 1984; Carta et al., 2006), or
decreased (Frechilla et al., 2001; Aguiar et al., 2006, 2008). As
detailed in Figure 1, studies performed in different animalmodels
report unequal modification in serotonergic receptor expression
along the BG nuclei. On the other hand, the DRN also suffers
adaptative changes after the dopaminergic degeneration, such
as increased 5-HT1A expression in MPTP monkeys (Frechilla
et al., 2001) or weaker inhibitory effects of 5-HT1A agonists on
neuron activity in rats (Wang et al., 2009). Electrophysiological
studies using different 6-hydroxydopamine (6-OHDA) lesion
models have shown increased basal firing rate of serotonergic
cells in the parkinsonian state (Zhang et al., 2007a; Kaya et al.,
2008; Wang et al., 2009; Prinz et al., 2013), while others show
decreases (Guiard et al., 2008) or no changes (Miguelez et al.,
2011).
In spite of the disparity of results, it seems clear that to vary-
ing extents, the serotonergic system is affected in parkinsonian
conditions. More clinical and preclinical studies using the same
experimental models and a greater amount of samples would help
to clarify the role of the serotonergic system in each stage of PD.
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FIGURE 1 | Simplified diagram of the basal ganglia circuits and altered
serotonergic receptor expression in pathological states. Changes found in
serotonergic receptor density in parkinsonian (left boxes) and dyskinetic (right
boxes) patients or animals models compared to control conditions. Each
nucleus and its modifications in receptor expression are encoded with the
same color. GABAergic inhibitory pathways are represented in dark blue and
glutamatergic excitatory pathways in red. Modulatory dopaminergic
connections are indicated in green and serotonergic pathways in brown.
DRN, dorsal raphe nucleus; GPi (EP), internal segment of the globus pallidus
(entopeduncular nucleus); GPe, external segment of the globus pallidus; STN,
subthalamic nucleus; SNc, substantia nigra pars compacta; SNr, substantia
nigra pars reticulata. r, rodent; m, monkey; h, human.
SEROTONERGIC SYSTEM IN L-DOPA INDUCED DYSKINESIA
The dopamine precursor L-DOPA is the most effective pharma-
cological treatment for PD, but it does not stop the progression
of the disease. Moreover, long-term administration of L-DOPA
induces motor complications, known as L-DOPA induced dyski-
nesias (LID), which have been related to adaptive changes of the
serotonergic system. For example, a recent publication revealed
that patients who had developed dyskinetic movements showed
significant serotonergic hyperinnervation in the GPe and caudate,
in comparison to non-dyskinetic individuals (Rylander et al.,
2010). Such sprouting was directly correlated with the severity of
motor complications. In contrast, other studies have shown that
striatal postmortem content of 5-HT and SERT levels did not differ
significantly between dyskinetic and non-dyskinetic cases (Calon
et al., 2003; Kish et al., 2008), and chronic L-DOPA treatment did
not influence SERT expression (Politis et al., 2010). As for sero-
tonergic receptors, a study performed in PD patients that followed
L-DOPA treatment showed increased 5-HT1A expression in sev-
eral cortical areas, while no modification in the striatum, GP, SN,
or thalamus was reported (Huot et al., 2012b). In the SNr, 5-HT2C
expression has also been observed to be raised in those patients
(Fox and Brotchie, 2000).
The use of animal models has provided valuable data to
better understand the physiopathological mechanisms of LID.
The most used models include non-human primates injected
with MPTP and rodent-models with hemilateral dopaminer-
gic loss chronically treated with L-DOPA. Although differences
may arise from the methodological protocols, such models are
considered to reproduce resembling symptoms and molecular
changes to those observed in PD patients and efficiently respond
to antidyskinetic therapy (Iderberg et al., 2012). It is now well
known that exogenously administered L-DOPA can be stored,
transformed into dopamine, and released from serotonergic ter-
minals to multiple brain regions, including the striatum, in an
uncontrolled manner, producing a non-physiological stimulation
of sensitized dopaminergic receptors (Arai et al., 1995; Carta
et al., 2007; Yamada et al., 2007; Navailles et al., 2010b, 2013).
Lesions of the DRN consistently prevent the expression of dyski-
nesia (Carta et al., 2007; Eskow et al., 2009) or dopamine release
after an acute L-DOPA injection (Navailles et al., 2010b). This
interaction between serotonergic and dopaminergic systems is
reciprocal, as 5-HT levels also decrease after L-DOPA administra-
tion, and L-DOPA itself can antagonize the effect of serotonergic
agents (Bartholini et al., 1968; Everett and Borcherding, 1970;
Commissiong and Sedgwick, 1979; Borah and Mohanakumar,
2007; Navailles et al., 2010a; Riahi et al., 2011; Miguelez et al.,
2013). In dyskinetic animals, SERT expression has been found
to be up-regulated (Rylander et al., 2010), not modified (Prinz
et al., 2013), or decreased (Nevalainen et al., 2011). Serotonergic
receptor expression in the BG is unevenly modified with L-DOPA
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treatment: 5-HT2A and 5-HT1B receptor expression is increased
(Zhang et al., 2008; Riahi et al., 2011, 2013; Huot et al., 2012c),
while 5-HT1A receptor expression is increased (Huot et al., 2012a)
or does not change (Riahi et al., 2012) (Figure 1). The primary
modifications occurring in the serotonergic system are thought
to take place at terminal levels because no changes in the number
of serotonergic neurons (Rylander et al., 2010; Inden et al., 2012)
or 5-HT or dopamine levels in the DRN of dyskinetic rats have
been reported (Bishop et al., 2012).
CLINICAL RELEVANCE
Although motor complications appear in the majority of the
patients that receive chronic treatment with L-DOPA, an effec-
tive pharmacological tool for avoiding or treating LID expression
is still missing. In this sense, 5-HT1A/1C receptors, which are
involved in the regulation of the ectopic dopamine release, are
envisaged as promising targets. In 6-OHDA-lesioned rats and
MPTP monkeys chronically treated with L-DOPA, 5-HT1A/1C
receptor agonists reduce expression of LID without impair-
ing L-DOPA improvement in motor performance (Bibbiani
et al., 2001; Ba et al., 2007; Dupre et al., 2007). Furthermore,
administration of the 5-HT1A agonist, 8-OH-DPAT, also pre-
vents L-DOPA-induced increment of extracellular dopamine
(Nahimi et al., 2012). Other drugs that modulate 5-HT neu-
rotransmission have shown efficacy over LID. Thus, a recent
study has revealed that the treatment with the precursor of
5-HT, 5-hydroxytryptophan reduces the appearance of LID in
L-DOPA-primed rats (Tronci et al., 2013). The 5-HT2A recep-
tor inverse agonist ACP-103 reduces tremor in rodents and
LID in MPTP monkeys (Vanover et al., 2008). Acute and
prolonged SSRI treatment attenuates the severity and develop-
ment of LID in L-DOPA-primed and naive rats without inter-
fering with motor improvement, which may be mediated in
part by 5-HT1A receptors (Bishop et al., 2012; Conti et al.,
2014). In contrast, in PD patients, while buspirone, a par-
tial 5-HT1A agonist, ameliorates dyskinesia (Kleedorfer et al.,
1991; Bonifati et al., 1994), sarizotan, another 5-HT1A recep-
tor agonist, failed to improve it compared with placebo (Goetz
et al., 2008) and significantly increased off time (Goetz et al.,
2007).
CONCLUDING REMARKS
The effects of 5-HT in the BG depend on the specific nucleus and
its receptor distribution. 5-HT induces an inhibition of MSN in
the striatum using either direct or indirect activation of seroton-
ergic receptors, as well as in the STN and SNr in vivo. In contrast,
in the GPe the overall effect of 5-HT is excitatory. In other nuclei
such as the EP or SNc the net effect is still not well understood.
The serotonergic physiological modulation may be modi-
fied in pathological conditions where the BG nuclei are highly
affected. Here, we provide data regarding the alteration of the
serotonergic system in PD, pointing out important discrepancies
about the relationship between the serotonergic and dopaminer-
gic systems in pathological states. In this concern, key method-
ological differences such as the use of different animal species and
models, pharmacological treatments or stage of the disease in PD
patients may explain these inconsistencies.
In summary, the serotonergic system is implicated in the mod-
ulation of the BG activity and in the etiopathology of PD and LID.
However, although in preclinical studies results indicate that sero-
tonergic drugs may be suitable for treating LID, this fact has yet to
be supported by clinical trials. Accordingly, further investigation
is required to determine the most suitable serotonergic target to
treat these motor disturbances.
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